Maia Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MAIA PHARMS INC, and what generic alternatives to MAIA PHARMS INC drugs are available?
MAIA PHARMS INC has nine approved drugs.
There are nine US patents protecting MAIA PHARMS INC drugs.
There are four patent family members on MAIA PHARMS INC drugs in three countries and seventy-two supplementary protection certificates in nine countries.
Summary for Maia Pharms Inc
| International Patents: | 4 |
| US Patents: | 9 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 9 |
Drugs and US Patents for Maia Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maia Pharms Inc | SINCALIDE | sincalide | POWDER;INTRAVENOUS | 210850-001 | Nov 22, 2022 | AP | RX | Yes | Yes | 11,737,983 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Maia Pharms Inc | SINCALIDE | sincalide | POWDER;INTRAVENOUS | 210850-001 | Nov 22, 2022 | AP | RX | Yes | Yes | 11,110,063 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-001 | Jul 27, 2022 | DISCN | Yes | No | 11,679,119 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Maia Pharms Inc | BACLOFEN | baclofen | INJECTABLE;INTRATHECAL | 210315-001 | Jul 30, 2019 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-002 | Jul 27, 2022 | DISCN | Yes | No | 11,679,119 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MAIA PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
International Patents for Maia Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2023049346 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2019040904 | ⤷ Subscribe |
| European Patent Office | 3672616 | ⤷ Subscribe |
| Canada | 3073944 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Maia Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0290047 | 97C0108 | Belgium | ⤷ Subscribe | PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522 |
| 0489070 | 22/2004 | Austria | ⤷ Subscribe | PRODUCT NAME: BIVALIRUDIN UND TRIFLUORACETAT DAVON; REGISTRATION NO/DATE: EU/1/04/289/001 20040920 |
| 2666774 | LUC00167 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: RELEBACTAM, EVENTUELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE, EVENTUELLEMENT SOUS FORME DE SEL DE SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/19/1420 20200217 |
| 2563920 | CR 2019 00001 | Denmark | ⤷ Subscribe | PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
